Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study
暂无分享,去创建一个
[1] Jing Shen,et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial , 2007, The Lancet.
[2] D. Hassiakos,et al. Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. , 2006, European journal of obstetrics, gynecology, and reproductive biology.
[3] M. V. Van Allen,et al. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. , 2005, Birth defects research. Part A, Clinical and molecular teratology.
[4] V. Massa,et al. Study on the common teratogenic pathway elicited by the fungicides triazole-derivatives. , 2005, Toxicology in vitro : an international journal published in association with BIBRA.
[5] K. Rothman,et al. Risk of specific congenital abnormalities in offspring of women with diabetes , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[6] J. Sobel,et al. Fluconazole for the treatment of candidiasis: 15 years experience , 2004, Expert review of anti-infective therapy.
[7] W. Inman,et al. Safety of fluconazole in the treatment of vaginal candidiasis , 2004, European Journal of Clinical Pharmacology.
[8] J. Sobel,et al. Antifungal drugs in pregnancy: a review , 2003, Expert opinion on drug safety.
[9] H. Sørensen,et al. Predictive value and completeness of the registration of congenital abnormalities in three Danish population-based registries , 2003, Scandinavian journal of public health.
[10] A. Mitchell. Special Considerations in Studies of Drug‐induced Birth Defects , 2002 .
[11] K. Jones,et al. Selection bias in Teratology Information Service pregnancy outcome studies. , 2001, Teratology.
[12] E. Menegola,et al. Antifungal triazoles induce malformations in vitro. , 2001, Reproductive toxicology.
[13] L. Pedersen,et al. Birth outcomes in women exposed to anticonvulsant drugs , 2000, Acta neurologica Scandinavica.
[14] H. Sørensen,et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. , 1999, British journal of clinical pharmacology.
[15] S. Jick. Pregnancy Outcomes after Maternal Exposure to Fluconazole , 1999, Pharmacotherapy.
[16] J. Olsen,et al. The Danish Medical Birth Registry. , 1998, Danish medical bulletin.
[17] D. Bartley,et al. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. , 1997, American journal of medical genetics.
[18] M. Bonati,et al. Fluconazole Treatment for Vulvovaginal Candidiasis during Pregnancy , 1997, The Annals of pharmacotherapy.
[19] P. Mastroiacovo,et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. , 1996, American journal of obstetrics and gynecology.
[20] J. Abraham,et al. Fluconazole-induced congenital anomalies in three infants. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] J. Fleiss,et al. The statistical basis of meta-analysis. , 1993, Statistical methods in medical research.
[22] A. R. Murthy,et al. Congenital malformations in an infant born to a woman treated with fluconazole. , 1992, The Pediatric infectious disease journal.
[23] Gillian M. Morriss-Kay,et al. Langman's Medical Embryology , 1991 .
[24] P. Vanparys,et al. Safety aspects of oral antifungal agents. , 1990, British journal of clinical practice. Supplement.
[25] E. Niebuhr,et al. Down's syndrome , 1974, Humangenetik.